There are currently 2708 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy
NCT05467683
Recruiting
Anxiety-, obsessive-compulsive and trauma- and stressor-related disorders reflect a significant public health problem. This study is designed to evaluate the predictive power of a novel biomarker based on a CO2 challenge, thus addressing the central question "can this easy-to-administer assay aid clinicians in deciding whether or not to initiate exposure-based therapy?"
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/18/2025
Locations: Boston University, Boston, Massachusetts
Conditions: Obsessive-Compulsive Disorder, Post Traumatic Stress Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder
Register for Updates
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
NCT05726370
Recruiting
This research study is evaluating effectiveness and safety of a combination of immunotherapy drug, pembrolizumab, with chemotherapy, as a possible treatment before and after surgery for squamous cell carcinoma of the head and neck (HNSCC). The combination of pembrolizumab and chemotherapy will be given prior to your surgery, while immunotherapy pembrolizumab will be continued for approximately 1 year after surgery. The names of the study drugs involved in this research study are: * pembrolizum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Resectable Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck
Register for Updates
SPEARHEAD-3 Pediatric Study
NCT05642455
Recruiting
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
06/18/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Osteosarcoma, Neuroblastoma (NBL)
Register for Updates
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
NCT05804318
Recruiting
This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Prostate Cancer
Register for Updates
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
NCT06096116
Recruiting
The primary objective of this study is to evaluate the efficacy of two different doses of Atenativ, versus placebo, in restoring and maintaining heparin responsiveness in adult patients undergoing cardiac surgery necessitating cardiopulmonary bypass (CPB)
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/18/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Acquired Antithrombin Deficiency
Register for Updates
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
NCT05919511
Recruiting
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Massachusetts Cancer Research Center, Boston, Massachusetts
Conditions: cGVHD
Register for Updates
Novel Digital Application for Patients With Acute Leukemia
NCT06472128
Recruiting
This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/18/2025
Locations: Massachusetts General Hospital (MGH), Boston, Massachusetts
Conditions: Relapsed Adult Acute Myeloid Leukemia, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
Register for Updates
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478
Recruiting
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approxi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
NCT06483334
Recruiting
This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the safety and preliminary efficacy of sacituzumab tirumotecan plus enfortumab vedotin (EV). Part 2 will be based on Part 1 results and will evaluate the efficacy, pharmacokinetics, and safety of sacituzumab tirumotecan plus EV in combination with pembrolizumab in participants with advanced urothelial carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Dana-Farber Cancer Institute ( Site 4047), Boston, Massachusetts
Conditions: Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Register for Updates
Improving Coronary Vascular Health in Women
NCT06843902
Recruiting
Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed. We are conducting a study randomizing women with HIV and either diabetes, chronic kidney disease, or both to health educati... Read More
Gender:
FEMALE
Ages:
Between 45 years and 75 years
Trial Updated:
06/18/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: HIV-1-infection, Coronary Microvascular Dysfunction, Metabolic Disease
Register for Updates
SHARE Program: SUSTAIN
NCT06934395
Recruiting
The goal of PROJECT SUSTAIN is to optimize Healthy Choices to advance an adaptive and scalable intervention designed to improve self-management of alcohol and HIV in Young People with HIV (YPWH) while understanding the context for state-wide implementation and sustainment in a Hybrid Experimental Design (HED). SUSTAIN utilizes mHealth and telehealth intervention delivery of Healthy Choices (HC), combined with text messaging between sessions, to increase the likelihood of daily medication adheren... Read More
Gender:
ALL
Ages:
Between 18 years and 29 years
Trial Updated:
06/18/2025
Locations: Northeastern University, Boston, Massachusetts
Conditions: Hiv
Register for Updates
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379
Recruiting
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
06/18/2025
Locations: Boston Clinical Trials Llc, Boston, Massachusetts
Conditions: Major Depressive Disorder
Register for Updates